Named Bioactive Compounds · Compound
Purpurin
Moderate Evidencecompound
Hermetica Superfood Encyclopedia
Purpurin is a naturally occurring anthraquinone pigment found primarily in the roots of Rubia tinctorum (madder plant), where it exerts biological activity through radical scavenging, serine protease inhibition, and modulation of cytochrome P450 enzymes. Its primary mechanisms involve direct free radical neutralization and interference with metabolic activation pathways responsible for dietary mutagen toxicity.
Purpurin (1,2,4-trihydroxyanthraquinone) is a naturally occurring anthraquinone derivative found in the roots of the madder plant (Rubia tinctorum), where it exists as colorless glycosides alongside alizarin. It can also be synthetically produced from 9,10-anthraquinone through hydroxylation and is available commercially at ≥95% purity.
The available research dossier contains no human clinical trials, randomized controlled trials (RCTs), or meta-analyses with PubMed PMIDs for purpurin. Current evidence is limited to in vitro bacterial mutagenicity assays and mechanistic studies without human clinical validation.
No clinically studied dosage ranges for human use are available in the current research. Commercial products are available as purpurin ≥95% powder in 5g and 10g quantities, but therapeutic dosages have not been established through clinical trials. Consult a healthcare provider before starting any new supplement.
Purpurin (1,2,4-trihydroxyanthraquinone; C₁₄H₈O₅; MW 256.21 g/mol) is not a nutritional substance per se but a naturally occurring anthraquinone pigment. It is found primarily in the root of madder (Rubia tinctorum), typically at concentrations of approximately 0.1–3.0% of dried root weight depending on plant maturity, growing conditions, and extraction method. Key bioactive characteristics: • Three hydroxyl groups at positions 1, 2, and 4 on the anthraquinone scaffold confer its radical-scavenging (antioxidant) capacity, with reported DPPH IC₅₀ values in the range of ~15–50 µM in vitro. • It is lipophilic (logP ~2.1–2.5), which favors membrane permeability but limits aqueous solubility (~0.05 mg/mL in water at 25 °C); solubility improves in ethanol and DMSO. • Oral bioavailability in humans is poorly characterized; animal pharmacokinetic studies suggest moderate absorption with hepatic glucuronidation and sulfation as primary phase II metabolic pathways, leading to relatively rapid clearance. • No macronutrient value (no protein, fat, carbohydrate, or fiber contribution at doses typically encountered). • No meaningful vitamin or mineral content intrinsic to the compound itself. • When consumed as part of whole madder root preparations, co-occurring compounds include alizarin, pseudopurpurin, rubiadin, lucidin, and various glycosides (e.g., ruberythric acid), which may collectively modulate bioavailability and biological activity through synergistic or competitive interactions. • Purpurin chelates divalent metal ions (notably Ca²⁺, Fe²⁺/Fe³⁺, Al³⁺), which can influence both its own bioavailability and the absorption of dietary minerals. • Estimated dietary exposure from traditional madder-containing herbal preparations is in the low milligram range per dose; it is not present in appreciable amounts in common foods outside of niche traditional remedies. • Safety note: structurally related anthraquinones (e.g., lucidin) from Rubia species have shown genotoxic potential; purpurin itself has mixed genotoxicity data, warranting caution regarding concentrated supplementation.
Purpurin scavenges reactive oxygen species via its hydroxylated anthraquinone ring structure, donating hydrogen atoms to neutralize free radicals such as DPPH and superoxide. It inhibits serine proteases by competing at the active site serine residue, potentially disrupting inflammatory and coagulation cascades. Additionally, purpurin modulates CYP1A1 and CYP1A2 enzyme activity, reducing the bioactivation of heterocyclic amines like 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) into their mutagenic forms, as demonstrated in Salmonella typhimurium Ames assay models.
Evidence for purpurin's health effects is entirely preclinical, with no published human clinical trials as of 2024. In vitro antioxidant studies using DPPH and ABTS assays demonstrate measurable radical scavenging activity, though IC50 values and comparisons to reference antioxidants vary across studies. Bacterial mutagenicity assays (Ames test with S. typhimurium TA98 and TA100 strains) show dose-dependent inhibition of PhIP and IQ-induced mutagenicity, suggesting CYP450-mediated protection against food-derived carcinogens. Preliminary cell-based studies indicate potential effects on adipocyte differentiation pathways, though mechanisms and magnitudes remain incompletely characterized, making any translation to human dosing or outcomes premature.
Purpurin has no established safe dosage range for human consumption, and no formal toxicological profile exists from controlled clinical studies. As a CYP1A1 and CYP1A2 modulator, purpurin carries a theoretical risk of pharmacokinetic interactions with drugs metabolized by these enzymes, including certain antidepressants, antipsychotics, and caffeine. The parent plant Rubia tinctorum contains lucidin, a genotoxic anthraquinone, raising concern about contamination in crude madder-derived extracts; isolated purpurin itself has shown mutagenic potential in some bacterial assay conditions. Purpurin supplementation is not recommended during pregnancy or breastfeeding due to the complete absence of safety data and the known genotoxic risk profile of related anthraquinone compounds.
